Health ❯ Healthcare ❯ Chronic Diseases

Obesity

Weight Management Treatment Options Type 2 Diabetes Comorbidities Diabetes Health Complications Public Health Management Strategies Economic Impact of Obesity Semaglutide

Biomea Fusion Reports Positive 52-Week Phase II Results for Icovamenib in Diabetes

Company-presented ATTD findings will guide dosing decisions for follow-on Phase II trials targeting defined patient groups.

Oral Semaglutide Cuts Serious Heart-Failure Events 22% in Type 2 Diabetes With Heart Failure

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

New Review Finds Rapid Weight Return After Stopping GLP-1 Weight-Loss Drugs

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

Oxford BMJ Review Finds Rapid Weight Rebound After Stopping Modern Weight-Loss Drugs

FDA Approves First Oral Weight-Loss GLP-1: Wegovy Pill to Launch in January

EMA Panel Backs Higher 7.2 mg Wegovy Dose for Obesity

Mexico Launches PRONAM to Standardize Care Across Public Health Services

Oral Semaglutide 25 mg Shows Larger Metabolic Gains With At Least 15% Weight Loss in OASIS-4

Amgen Raises Outlook on Q3 Beat as MariTide Milestones Approach

Innovent Says Mazdutide Tops Semaglutide in China Phase 3 Diabetes Trial

WHO Adds GLP-1 Drugs and Cancer Immunotherapies to Essential Medicines List

Munich Pharmacy Offers Walk-In Flu and COVID Shots Today Ahead of Oktoberfest

ESC Data Tie Wegovy and Mounjaro to Lower HFpEF Hospitalization and Death, With Novo Citing CV Edge for Wegovy

Four in Ten Argentine Adults Have High Cholesterol, UBA Clinicians Warn

GLP-1 Agonists Cut Dementia and Mortality Risk Versus Metformin in Type 2 Diabetes

SYNT-101 Shows Promise in Early Human Trials as a Non-Invasive Obesity Treatment

Eli Lilly Launches Mounjaro in India to Address Obesity and Diabetes

Novo Nordisk Launches Wegovy in France Without Reimbursement